Bionano Genomics, Inc. (BNGO) |
|
1.1 0.01 (0.92%)
|
03-24 16:00 |
|
Open: |
1.07 |
Pre. Close: |
1.09 |
|
High:
|
1.13 |
Low:
|
1.06 |
|
Volume:
|
2,912,973 |
Market Cap:
|
337(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:24:29 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 1.59  One year: 1.81 |
| Support: |
Support1: 1.05 Support2: 0.88 |
| Resistance: |
Resistance1: 1.36 Resistance2: 1.54 |
| Pivot: |
1.19 |
| Moving Average: |
MA(5): 1.1 MA(20): 1.22
MA(100): 1.76 MA(250): 1.89 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 8.2 %D(3): 10 |
| RSI: |
RSI(14): 33 |
| 52-week: |
High: 4.34 Low: 1.05 |
| Average Vol(K): |
3-Month: 6,448 (K) 10-Days: 5,332 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BNGO ] has closed above bottom band by 23.2%. Bollinger Bands are 42.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.13 - 1.14 |
1.14 - 1.14 |
|
Low:
|
1.05 - 1.05 |
1.05 - 1.06 |
|
Close:
|
1.09 - 1.1 |
1.1 - 1.11 |
|
Company Description |
|
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California. |
Headline News |
Fri, 24 Mar 2023
Bionano Genomics Inc. (BNGO) Stock: A Guide to the Market Trend - The News Heater
Wed, 22 Mar 2023
Bionano Announces First Study Using OGM to Discover Structural Variants with Potential Relevance to Genetic Diagnosis of MRKH Syndrome, a Syndrome Impacting Reproductive System Development in 1 in 4,500 Females - Yahoo Finance
Tue, 21 Mar 2023
What is Bionano Genomics Inc. (BNGO) Stock Return on ... - SETE News
Mon, 20 Mar 2023
BioNano Genomics Inc (BNGO) has fallen -11.11% in a Week, Should You Hold? - InvestorsObserver
Fri, 17 Mar 2023
BioNano Genomics Inc (BNGO) has risen 3.48% Friday In Premarket Trading - InvestorsObserver
Mon, 13 Mar 2023
Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) Annual Meeting Featuring OGM Utility Across a Broad Range of Research Applications - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Diagnostics & Research |
| Shares Out. |
306 (M) |
| Shares Float |
301 (M) |
|
% Held by Insiders
|
1.8 (%) |
|
% Held by Institutions
|
27.8 (%) |
|
Shares Short
|
57,650 (K) |
|
Shares Short P.Month
|
52,260 (K) |
Stock Financials |
|
EPS
|
-0.42 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.83 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-466.1 |
|
Return on Assets (ttm)
|
-23.7 |
|
Return on Equity (ttm)
|
-45.3 |
|
Qtrly Rev. Growth
|
30.3 |
|
Gross Profit (p.s.)
|
0.01 |
|
Sales Per Share
|
0.09 |
|
EBITDA (p.s.)
|
-0.4 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-125 (M) |
|
Levered Free Cash Flow
|
-61 (M) |
Stock Valuations |
|
PE Ratio
|
-2.62 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.3 |
|
Price to Sales
|
12.11 |
|
Price to Cash Flow
|
-2.7 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
